Woodford Investment Management is a privately owned investment firm manages equity mutual funds.
Business Model:
Revenue: $2.1M
Employees: 11-50
Address: 9400 Garsington Road
City: Oxford
State: england
Zip: OX4
Country: GB
Woodford Investment Management is a privately owned investment firm manages equity mutual funds. At Woodford, they don’t want to be just another fund management company. They want to create something different and better for their investors and they feel strongly that existing and potential clients are entitled to understand what they are doing with their money. As investors, they are active, engaged, long-term, disciplined, diligent and focused. That’s a lot of things to say about their selves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along. Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2017 | RateSetter | Venture Round | 16.7M |
3/2015 | RateSetter | Venture Round | 29.6M |
3/2018 | OxSyBio | Series A | 13.9M |
10/2014 | Spin Memory | Private Equity Round | 70M |
4/2015 | Northwest Biotherapeutics | Post-IPO Equity | 40M |
10/2014 | Cosmederm Bioscience | Private Equity Round | 50M |
7/2015 | Seedrs | Series A | 11.7M |
3/2016 | NovaBiotics | Venture Round | 4.3M |
9/2015 | CeQur | Series C | 100M |
4/2018 | BenevolentAI | Funding Round | 0 |
7/2017 | HaloSource | Post-IPO Equity | 2.2M |
11/2014 | Northwest Biotherapeutics | Post-IPO Equity | 35M |
5/2016 | Drayson Technologies Group | Series B | 11.6M |
7/2017 | Drayson Technologies Group | Series C | 19.3M |
9/2015 | AMO Pharma | Private Equity Round | 25M |
12/2018 | Genomics | Series B | 9.1M |
5/2006 | Oxford Nanopore Technologies | Series A | 14.5M |
11/2015 | Ultraleap | Series A | 15.6M |
11/2014 | Genomics | Series A | 16.2M |
3/2018 | Metalysis | Venture Round | 16.9M |
8/2015 | BenevolentAI | Venture Round | 0 |
8/2014 | Oxford Nanopore Technologies | Venture Round | 58.8M |
12/2018 | Ultraleap | Series C | 0 |
9/2018 | LIGNIA Wood Company | Venture Round | 0 |
3/2016 | Autolus | Series B | 56.7M |
8/2016 | Evofem Biosciences | Post-IPO Equity | 25M |
10/2016 | Carrick Therapeutics | Series A | 95M |
1/2015 | NovaBiotics | Venture Round | 7.6M |
4/2015 | SciFluor Life Sciences | Series B | 30M |
6/2018 | Metaboards | Series A | 0 |
11/2018 | Spin Memory | Series B | 52M |
7/2015 | ReNeuron Group | Post-IPO Equity | 106.1M |
8/2014 | PurpleBricks | Series B | 13.4M |
3/2019 | Inivata | Series B | 0 |
8/2016 | Cambridge Innovation Capital | Venture Round | 75M |
9/2017 | Seedrs | Series A | 5.2M |
7/2016 | Econic Technologies | Venture Round | 6.5M |
5/2017 | Gigaclear | Private Equity Round | 144.1M |
11/2014 | Kuur Therapeutics | Series B | 78.5M |
3/2017 | Kuur Therapeutics | Series C | 73.7M |
2/2016 | MISSION Therapeutics | Series C | 86.5M |
5/2015 | Akamis Bio | Series C | 38.8M |
10/2015 | Theravance Biopharma | Post-IPO Equity | 55M |
5/2015 | Kymab | Series B | 50M |
1/2016 | Inivata | Series A | 45.2M |
5/2016 | Nexeon | Private Equity Round | 43.2M |
7/2015 | Immunocore | Series A | 320M |
8/2018 | Genomics | Series B | 32.5M |
1/2018 | Bodle Technologies | Series A | 8.5M |
10/2016 | eve Sleep | Series B | 18.3M |
11/2016 | Kymab | Series C | 0 |
5/2017 | Ultraleap | Series B | 23M |
2/2016 | Federated Wireless | Series A | 22M |
11/2015 | Atom Bank | Venture Round | 123.7M |
3/2017 | Atom Bank | Venture Round | 102.1M |
7/2019 | Atom Bank | Venture Round | 0 |
10/2015 | Precision Biopsy | Series B | 33.6M |
2/2018 | Econic Technologies | Venture Round | 9.7M |
7/2015 | Mereo Biopharma | Private Equity Round | 119M |
9/2017 | Autolus | Series C | 80M |
7/2019 | Atom Bank | Venture Round | 0 |
3/2019 | Inivata | Series B | 0 |
12/2018 | Genomics | Series B | 0 |
12/2018 | Ultraleap | Series C | 0 |
11/2018 | Spin Memory | Series B | 0 |
9/2018 | LIGNIA Wood Company | Venture Round | 0 |
8/2018 | Genomics | Series B | 0 |
6/2018 | Metaboards | Series A | 0 |
4/2018 | BenevolentAI | Funding Round | 0 |
3/2018 | Metalysis | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|